Outnumbered: Control Prothrombin Time in Maddrey’s Discriminant Function Impacts Steroid Use but Not Mortality in Alcoholic Hepatitis
Background and aims: In alcoholic hepatitis (AH), increases in the total bilirubin (TB) and the prothrombin time (PT), which are included in the Maddrey’s discriminant function (MDF) and the model for end-stage liver disease (MELD), are associated with poor outcomes. However, the impact of which con...
Uloženo v:
| Vydáno v: | Biology (Basel, Switzerland) Ročník 11; číslo 12; s. 1833 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
MDPI AG
16.12.2022
MDPI |
| Témata: | |
| ISSN: | 2079-7737, 2079-7737 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background and aims: In alcoholic hepatitis (AH), increases in the total bilirubin (TB) and the prothrombin time (PT), which are included in the Maddrey’s discriminant function (MDF) and the model for end-stage liver disease (MELD), are associated with poor outcomes. However, the impact of which control PT in the MDF to use compared to the MELD on the outcomes in AH is unknown. Our aim is to determine whether the choice of the control PT used in the MDF calculations has any impact on steroid use and survival when compared to the MELD in those with AH. Methods: Through retrospective chart review, we analyzed 882 subjects who were admitted from 2012 to 2020 with acute AH. Their MDF was calculated [(TB + 4.6 × (PT–control)] using the following three different control PTs: 12, 13.5, and 14.8 s, and was compared to the MELD. The primary outcomes were steroid use and 30-day survival. Results: When it was stratified by the control PT, the percentage of MDF ≥ 32 (the threshold for steroids) decreased with increasing control PT (70%, 61%, and 52%, respectively), along with decreased steroid use (91%, 84%, and 75%, respectively). Those who received steroids were not shown to have improved 30-day survival compared to those who did not receive steroids (p = 0.41). The ability of the MDF for each control PT threshold to predict 30-day survival was similar (AUROC 0.735), and was lower compared to the MELD (0.767). Conclusion: While the choice of PT control in the MDF impacted the use of steroids in AH, the use of steroids and the choice of PT control used did not impact the overall survival. Regardless of which control PT was used in the MDF, the MELD was better at predicting 30-day survival. Important information: Background: Treatment with steroids is indicated in alcoholic hepatitis (AH) with Maddrey discriminant function (MDF) ≥ 32 and the model for end-stage liver disease (MELD) ≥ 20. The impact that the control prothrombin time (PT) value that is used in MDF has on steroid use and survival in AH is poorly understood. Findings: The choice of control PT that is used when calculating the MDF impacts the use of steroids but does not impact mortality. The MELD was better than the MDF at any control PT used in predicting survival in acute AH. Implications for patient care: Providers should be aware that higher control PT’s have an effect on treatment decisions but should not generally impact survival in this population. The MELD appears to better predict 30-day survival in this population. |
|---|---|
| AbstractList | Background and aims: In alcoholic hepatitis (AH), increases in the total bilirubin (TB) and the prothrombin time (PT), which are included in the Maddrey’s discriminant function (MDF) and the model for end-stage liver disease (MELD), are associated with poor outcomes. However, the impact of which control PT in the MDF to use compared to the MELD on the outcomes in AH is unknown. Our aim is to determine whether the choice of the control PT used in the MDF calculations has any impact on steroid use and survival when compared to the MELD in those with AH. Methods: Through retrospective chart review, we analyzed 882 subjects who were admitted from 2012 to 2020 with acute AH. Their MDF was calculated [(TB + 4.6 × (PT–control)] using the following three different control PTs: 12, 13.5, and 14.8 s, and was compared to the MELD. The primary outcomes were steroid use and 30-day survival. Results: When it was stratified by the control PT, the percentage of MDF ≥ 32 (the threshold for steroids) decreased with increasing control PT (70%, 61%, and 52%, respectively), along with decreased steroid use (91%, 84%, and 75%, respectively). Those who received steroids were not shown to have improved 30-day survival compared to those who did not receive steroids (p = 0.41). The ability of the MDF for each control PT threshold to predict 30-day survival was similar (AUROC 0.735), and was lower compared to the MELD (0.767). Conclusion: While the choice of PT control in the MDF impacted the use of steroids in AH, the use of steroids and the choice of PT control used did not impact the overall survival. Regardless of which control PT was used in the MDF, the MELD was better at predicting 30-day survival. Important information: Background: Treatment with steroids is indicated in alcoholic hepatitis (AH) with Maddrey discriminant function (MDF) ≥ 32 and the model for end-stage liver disease (MELD) ≥ 20. The impact that the control prothrombin time (PT) value that is used in MDF has on steroid use and survival in AH is poorly understood. Findings: The choice of control PT that is used when calculating the MDF impacts the use of steroids but does not impact mortality. The MELD was better than the MDF at any control PT used in predicting survival in acute AH. Implications for patient care: Providers should be aware that higher control PT’s have an effect on treatment decisions but should not generally impact survival in this population. The MELD appears to better predict 30-day survival in this population. In alcoholic hepatitis (AH), increases in the total bilirubin (TB) and the prothrombin time (PT), which are included in the Maddrey's discriminant function (MDF) and the model for end-stage liver disease (MELD), are associated with poor outcomes. However, the impact of which control PT in the MDF to use compared to the MELD on the outcomes in AH is unknown. Our aim is to determine whether the choice of the control PT used in the MDF calculations has any impact on steroid use and survival when compared to the MELD in those with AH.BACKGROUND AND AIMSIn alcoholic hepatitis (AH), increases in the total bilirubin (TB) and the prothrombin time (PT), which are included in the Maddrey's discriminant function (MDF) and the model for end-stage liver disease (MELD), are associated with poor outcomes. However, the impact of which control PT in the MDF to use compared to the MELD on the outcomes in AH is unknown. Our aim is to determine whether the choice of the control PT used in the MDF calculations has any impact on steroid use and survival when compared to the MELD in those with AH.Through retrospective chart review, we analyzed 882 subjects who were admitted from 2012 to 2020 with acute AH. Their MDF was calculated [(TB + 4.6 × (PT-control)] using the following three different control PTs: 12, 13.5, and 14.8 s, and was compared to the MELD. The primary outcomes were steroid use and 30-day survival.METHODSThrough retrospective chart review, we analyzed 882 subjects who were admitted from 2012 to 2020 with acute AH. Their MDF was calculated [(TB + 4.6 × (PT-control)] using the following three different control PTs: 12, 13.5, and 14.8 s, and was compared to the MELD. The primary outcomes were steroid use and 30-day survival.When it was stratified by the control PT, the percentage of MDF ≥ 32 (the threshold for steroids) decreased with increasing control PT (70%, 61%, and 52%, respectively), along with decreased steroid use (91%, 84%, and 75%, respectively). Those who received steroids were not shown to have improved 30-day survival compared to those who did not receive steroids (p = 0.41). The ability of the MDF for each control PT threshold to predict 30-day survival was similar (AUROC 0.735), and was lower compared to the MELD (0.767).RESULTSWhen it was stratified by the control PT, the percentage of MDF ≥ 32 (the threshold for steroids) decreased with increasing control PT (70%, 61%, and 52%, respectively), along with decreased steroid use (91%, 84%, and 75%, respectively). Those who received steroids were not shown to have improved 30-day survival compared to those who did not receive steroids (p = 0.41). The ability of the MDF for each control PT threshold to predict 30-day survival was similar (AUROC 0.735), and was lower compared to the MELD (0.767).While the choice of PT control in the MDF impacted the use of steroids in AH, the use of steroids and the choice of PT control used did not impact the overall survival. Regardless of which control PT was used in the MDF, the MELD was better at predicting 30-day survival. Important information: Background: Treatment with steroids is indicated in alcoholic hepatitis (AH) with Maddrey discriminant function (MDF) ≥ 32 and the model for end-stage liver disease (MELD) ≥ 20. The impact that the control prothrombin time (PT) value that is used in MDF has on steroid use and survival in AH is poorly understood.CONCLUSIONWhile the choice of PT control in the MDF impacted the use of steroids in AH, the use of steroids and the choice of PT control used did not impact the overall survival. Regardless of which control PT was used in the MDF, the MELD was better at predicting 30-day survival. Important information: Background: Treatment with steroids is indicated in alcoholic hepatitis (AH) with Maddrey discriminant function (MDF) ≥ 32 and the model for end-stage liver disease (MELD) ≥ 20. The impact that the control prothrombin time (PT) value that is used in MDF has on steroid use and survival in AH is poorly understood.The choice of control PT that is used when calculating the MDF impacts the use of steroids but does not impact mortality. The MELD was better than the MDF at any control PT used in predicting survival in acute AH.FINDINGSThe choice of control PT that is used when calculating the MDF impacts the use of steroids but does not impact mortality. The MELD was better than the MDF at any control PT used in predicting survival in acute AH.Providers should be aware that higher control PT's have an effect on treatment decisions but should not generally impact survival in this population. The MELD appears to better predict 30-day survival in this population.IMPLICATIONS FOR PATIENT CAREProviders should be aware that higher control PT's have an effect on treatment decisions but should not generally impact survival in this population. The MELD appears to better predict 30-day survival in this population. Simple SummaryAlcoholic hepatitis is associated with high morbidity and mortality. Maddrey’s discriminant function has been classically used to define the severity, with scores that are greater than 32 indicating poor outcomes and consideration for treatment with steroids. In order to use this calculation, a control prothrombin time is needed, which is not standardized across different electronic medical records or institutions. In this study, we aimed to determine if the control prothrombin time that is chosen has any effect on steroid use and mortality. We found that the higher the value of the control prothrombin time that was used, the less likely it was that individuals with alcoholic hepatitis would receive steroids. However, we found that this did not affect mortality in those who received steroids. This research is novel and important for providers to know when using Maddrey’s discriminant function, as the control PT values that they choose do have implications for treatment. Our findings also suggest that the model for end-stage liver disease (MELD) seems to be a better indicator of 30-day survival in this population.AbstractBackground and aims: In alcoholic hepatitis (AH), increases in the total bilirubin (TB) and the prothrombin time (PT), which are included in the Maddrey’s discriminant function (MDF) and the model for end-stage liver disease (MELD), are associated with poor outcomes. However, the impact of which control PT in the MDF to use compared to the MELD on the outcomes in AH is unknown. Our aim is to determine whether the choice of the control PT used in the MDF calculations has any impact on steroid use and survival when compared to the MELD in those with AH. Methods: Through retrospective chart review, we analyzed 882 subjects who were admitted from 2012 to 2020 with acute AH. Their MDF was calculated [(TB + 4.6 × (PT–control)] using the following three different control PTs: 12, 13.5, and 14.8 s, and was compared to the MELD. The primary outcomes were steroid use and 30-day survival. Results: When it was stratified by the control PT, the percentage of MDF ≥ 32 (the threshold for steroids) decreased with increasing control PT (70%, 61%, and 52%, respectively), along with decreased steroid use (91%, 84%, and 75%, respectively). Those who received steroids were not shown to have improved 30-day survival compared to those who did not receive steroids (p = 0.41). The ability of the MDF for each control PT threshold to predict 30-day survival was similar (AUROC 0.735), and was lower compared to the MELD (0.767). Conclusion: While the choice of PT control in the MDF impacted the use of steroids in AH, the use of steroids and the choice of PT control used did not impact the overall survival. Regardless of which control PT was used in the MDF, the MELD was better at predicting 30-day survival. Important information: Background: Treatment with steroids is indicated in alcoholic hepatitis (AH) with Maddrey discriminant function (MDF) ≥ 32 and the model for end-stage liver disease (MELD) ≥ 20. The impact that the control prothrombin time (PT) value that is used in MDF has on steroid use and survival in AH is poorly understood. Findings: The choice of control PT that is used when calculating the MDF impacts the use of steroids but does not impact mortality. The MELD was better than the MDF at any control PT used in predicting survival in acute AH. Implications for patient care: Providers should be aware that higher control PT’s have an effect on treatment decisions but should not generally impact survival in this population. The MELD appears to better predict 30-day survival in this population. In alcoholic hepatitis (AH), increases in the total bilirubin (TB) and the prothrombin time (PT), which are included in the Maddrey's discriminant function (MDF) and the model for end-stage liver disease (MELD), are associated with poor outcomes. However, the impact of which control PT in the MDF to use compared to the MELD on the outcomes in AH is unknown. Our aim is to determine whether the choice of the control PT used in the MDF calculations has any impact on steroid use and survival when compared to the MELD in those with AH. Through retrospective chart review, we analyzed 882 subjects who were admitted from 2012 to 2020 with acute AH. Their MDF was calculated [(TB + 4.6 × (PT-control)] using the following three different control PTs: 12, 13.5, and 14.8 s, and was compared to the MELD. The primary outcomes were steroid use and 30-day survival. When it was stratified by the control PT, the percentage of MDF ≥ 32 (the threshold for steroids) decreased with increasing control PT (70%, 61%, and 52%, respectively), along with decreased steroid use (91%, 84%, and 75%, respectively). Those who received steroids were not shown to have improved 30-day survival compared to those who did not receive steroids ( = 0.41). The ability of the MDF for each control PT threshold to predict 30-day survival was similar (AUROC 0.735), and was lower compared to the MELD (0.767). While the choice of PT control in the MDF impacted the use of steroids in AH, the use of steroids and the choice of PT control used did not impact the overall survival. Regardless of which control PT was used in the MDF, the MELD was better at predicting 30-day survival. Important information: Background: Treatment with steroids is indicated in alcoholic hepatitis (AH) with Maddrey discriminant function (MDF) ≥ 32 and the model for end-stage liver disease (MELD) ≥ 20. The impact that the control prothrombin time (PT) value that is used in MDF has on steroid use and survival in AH is poorly understood. The choice of control PT that is used when calculating the MDF impacts the use of steroids but does not impact mortality. The MELD was better than the MDF at any control PT used in predicting survival in acute AH. Providers should be aware that higher control PT's have an effect on treatment decisions but should not generally impact survival in this population. The MELD appears to better predict 30-day survival in this population. |
| Author | Healey, Marcus Sterling, Richard K. |
| AuthorAffiliation | 1 Internal Medicine, Virginia Commonwealth University (VCU) Health System, Richmond, VA 23219, USA 2 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University (VCU) Health System, Richmond, VA 23219, USA |
| AuthorAffiliation_xml | – name: 1 Internal Medicine, Virginia Commonwealth University (VCU) Health System, Richmond, VA 23219, USA – name: 2 Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University (VCU) Health System, Richmond, VA 23219, USA |
| Author_xml | – sequence: 1 givenname: Marcus orcidid: 0000-0003-2179-2935 surname: Healey fullname: Healey, Marcus – sequence: 2 givenname: Richard K. surname: Sterling fullname: Sterling, Richard K. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36552342$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkstuEzEUhkeoiJbQNTtkiQ2bUF9mxmMWSFWgNFJLkWjXlsc-kziasYPtQcqOHc_A6_EkOE2p2kgIb44v__nsc_w_Lw6cd1AULwl-y5jAJ631vV9sCCGUNIw9KY4o5mLKOeMHD-aHxXGMK5wHx7Rm9bPikNVVRVlJj4qfV2Ny49BCAPMOzbxLwffoS_BpGfzQWoeu7QAox0tlTIDN7x-_Ivpgow52sE65hM5Gp5P1Ds2HtdIpoq8JgrcG3URA7ZjQZ5_QpQ9J9TZttqjTXvul761G57BWySYbXxRPO9VHOL6Lk-Lm7OP17Hx6cfVpPju9mOqK4jQtW8E01RXG1OAOSM2gbVuDDdQCFDUqV2lKYjDhhvGmyysNnahZw8uOKGCTYr7jGq9Wcp2LUGEjvbLydsOHhVQhWd2DFFVHq5q0nHa8xKAVxUYBbk3JeIWFyKz3O9Z6bAfIF-Xmqf4R9PGJs0u58N-l4BmQv2JSvLkDBP9thJjkkBsLfa8c-DFK2jS8xpyQ8v9SXjUEC3pLfb0nXfkxuNzVraqu61JUW9Wrh4-_f_Vfa2TByU6gg48xQHcvIVhu_Sf3_Jczqr0MbZPaWiNXb_t_5v0BHm7jZg |
| CitedBy_id | crossref_primary_10_1007_s10620_024_08479_6 |
| Cites_doi | 10.1016/j.cgh.2013.06.013 10.1053/j.gastro.2016.02.042 10.1056/NEJMoa1101214 10.1016/0016-5085(78)90401-8 10.14309/ajg.0000000000001595 10.1056/NEJM199202203260802 10.1056/NEJMoa1412278 10.1002/hep.21607 10.1053/j.gastro.2015.04.044 10.14309/ajg.0000000000001596 10.1053/j.gastro.2009.04.062 10.3325/cmj.2021.62.17 10.7326/0003-4819-110-9-685 10.1136/flgastro-2018-101104 |
| ContentType | Journal Article |
| Copyright | 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022 |
| Copyright_xml | – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022 |
| DBID | AAYXX CITATION NPM 7QP 7TK 8FD 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 GNUQQ HCIFZ LK8 M7P P64 PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS RC3 7X8 7S9 L.6 5PM DOA |
| DOI | 10.3390/biology11121833 |
| DatabaseName | CrossRef PubMed Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database ProQuest Central Student SciTech Premium Collection Biological Sciences Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Genetics Abstracts Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts Biotechnology and BioEngineering Abstracts ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic Publicly Available Content Database PubMed AGRICOLA |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2079-7737 |
| ExternalDocumentID | oai_doaj_org_article_95f2561b72f740eca20dae0bd4375099 PMC9775026 36552342 10_3390_biology11121833 |
| Genre | Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | 2XV 53G 5VS 8FE 8FH AADQD AAFWJ AAHBH AAYXX ADBBV AFFHD AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI CCPQU CITATION EBD GROUPED_DOAJ HCIFZ HYE IAO IHR ITC KQ8 LK8 M48 M7P MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PROAC RPM ISR NPM 7QP 7TK 8FD ABUWG AZQEC DWQXO FR3 GNUQQ P64 PKEHL PQEST PQQKQ PQUKI PRINS RC3 7X8 PUEGO 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c520t-4b93c2c5002d0fe163ebbbd0de69ea2da000d41d017d378f00dcef963874f1ae3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000900517600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2079-7737 |
| IngestDate | Fri Oct 03 12:42:29 EDT 2025 Tue Nov 04 02:06:50 EST 2025 Sun Nov 09 09:26:20 EST 2025 Thu Sep 04 19:09:54 EDT 2025 Fri Jul 25 11:55:14 EDT 2025 Thu Jan 02 22:54:47 EST 2025 Tue Nov 18 20:56:28 EST 2025 Sat Nov 29 07:08:18 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | steroids Maddrey’s discriminant function (MDF) model for end-stage liver disease (MELD) prothrombin time (PT) alcoholic hepatitis (AH) |
| Language | English |
| License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c520t-4b93c2c5002d0fe163ebbbd0de69ea2da000d41d017d378f00dcef963874f1ae3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-2179-2935 |
| OpenAccessLink | https://www.proquest.com/docview/2756664956?pq-origsite=%requestingapplication% |
| PMID | 36552342 |
| PQID | 2756664956 |
| PQPubID | 2032427 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_95f2561b72f740eca20dae0bd4375099 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9775026 proquest_miscellaneous_2887607114 proquest_miscellaneous_2758109226 proquest_journals_2756664956 pubmed_primary_36552342 crossref_primary_10_3390_biology11121833 crossref_citationtrail_10_3390_biology11121833 |
| PublicationCentury | 2000 |
| PublicationDate | 20221216 |
| PublicationDateYYYYMMDD | 2022-12-16 |
| PublicationDate_xml | – month: 12 year: 2022 text: 20221216 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Biology (Basel, Switzerland) |
| PublicationTitleAlternate | Biology (Basel) |
| PublicationYear | 2022 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Veryan (ref_10) 2020; 11 Carithers (ref_5) 1989; 110 Altamirano (ref_6) 2022; 117 Rob (ref_13) 2021; 62 Bajaj (ref_3) 2022; 117 Ramond (ref_14) 1992; 326 Singal (ref_1) 2014; 12 Louvet (ref_8) 2009; 137 Thursz (ref_7) 2015; 372 Crabb (ref_2) 2016; 150 Louvet (ref_12) 2007; 45 Maddrey (ref_4) 1978; 75 Thevenot (ref_9) 2011; 365 Louvet (ref_11) 2015; 149 |
| References_xml | – volume: 12 start-page: 555 year: 2014 ident: ref_1 article-title: Alcoholic hepatitis: Current challenges and future directions publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2013.06.013 – volume: 150 start-page: 785 year: 2016 ident: ref_2 article-title: Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: Recommendation from the NIAAA Alcoholic Hepatitis Consortia publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.02.042 – volume: 365 start-page: 1781 year: 2011 ident: ref_9 article-title: Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1101214 – volume: 75 start-page: 193 year: 1978 ident: ref_4 article-title: Corticosteroid therapy of alcoholic hepatitis publication-title: Gastroenterology doi: 10.1016/0016-5085(78)90401-8 – volume: 117 start-page: 225 year: 2022 ident: ref_3 article-title: Acute-on-chronic liver failure clinical guidelines publication-title: Am. J. Gastroenterol. doi: 10.14309/ajg.0000000000001595 – volume: 326 start-page: 507 year: 1992 ident: ref_14 article-title: A randomized trial of prednisolone in patients with severe alcoholic hepatitis publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199202203260802 – volume: 372 start-page: 1619 year: 2015 ident: ref_7 article-title: Prednisolone or pentoxifylline for alcoholic hepatitis publication-title: New Engl. J. Med. doi: 10.1056/NEJMoa1412278 – volume: 45 start-page: 1348 year: 2007 ident: ref_12 article-title: The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids publication-title: Hepatology doi: 10.1002/hep.21607 – volume: 149 start-page: 398 year: 2015 ident: ref_11 article-title: Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.04.044 – volume: 117 start-page: 301 year: 2022 ident: ref_6 article-title: The MELD score is superior to the Maddrey discriminant function score to predict short-term mortality in alcohol-associated hepatitis: A global study publication-title: Am. J. Gastroenterol. doi: 10.14309/ajg.0000000000001596 – volume: 137 start-page: 541 year: 2009 ident: ref_8 article-title: Infection in patients with severe alcoholic hepatitis treated with steroids: Early response to therapy is the key factor publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.04.062 – volume: 62 start-page: 17 year: 2021 ident: ref_13 article-title: Comparison of prognostic scores for alcoholic hepatitis: A retrospective study publication-title: Croat. Med. J. doi: 10.3325/cmj.2021.62.17 – volume: 110 start-page: 685 year: 1989 ident: ref_5 article-title: Methylprednisolone therapy in patients with severe alcoholic hepatitis: A randomized multicenter trial publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-110-9-685 – volume: 11 start-page: 133 year: 2020 ident: ref_10 article-title: Recent advances in alcoholic hepatitis publication-title: Frontline Gastroenterol. doi: 10.1136/flgastro-2018-101104 |
| SSID | ssj0000702636 |
| Score | 2.2567527 |
| Snippet | Background and aims: In alcoholic hepatitis (AH), increases in the total bilirubin (TB) and the prothrombin time (PT), which are included in the Maddrey’s... In alcoholic hepatitis (AH), increases in the total bilirubin (TB) and the prothrombin time (PT), which are included in the Maddrey's discriminant function... Simple SummaryAlcoholic hepatitis is associated with high morbidity and mortality. Maddrey’s discriminant function has been classically used to define the... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1833 |
| SubjectTerms | alcoholic hepatitis alcoholic hepatitis (AH) Alcoholism Ascites Bilirubin Contraindications Creatinine Electronic medical records Hepatitis Hospitalization Laboratories Liver Liver diseases Maddrey’s discriminant function (MDF) Medical prognosis model for end-stage liver disease (MELD) Morbidity Mortality patient care Patients Prothrombin prothrombin time (PT) Steroid hormones Steroids Survival White people |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9VAFB6kVHAj1me0yggu3MQmk0kmcddWL3XRa0EL3YV5nGCgJnKTW-jOnb_Bv-cv6Tkz6eXe4mMjBEKSSUjmvL5DznyHsVc6T0EaYWNMvKpY5raITaLLWAHCZddUrrDSN5tQ83l5dladrLX6opqwQA8cJm6vyhuMyqlRolEyAatF4jQkxsmMgp1fuoeoZy2Z8j5YYW5B_yWJyyfDvH5v4jRC0yZQkG2EIc_W_zuIebNSci30zO6xuxNm5PvhXXfYLejus9uhi-TlA_bj43IMjT3AveWHofacnyx6aoHwFTNfTus8OO6P0c2g6H59_znwdy05jFAIw2cY3UhC_INfNDnwTzjdfev46QDcLEc-70d-7JE6onZ61H5ordtafgRUlD22w0N2Onv_-fAonvorxDYXyRhLU2VW2BydoksaQGQGxhiXOCgq0MJpnEcnU4dG6zJVNnhkoSGLVbJJNWSP2FbXd_CEcStkg9FWGSkraSCroHDUThTxgy0TpSP25nq6azuRj1MPjPMakxCST31DPhF7vbrhW-Dd-PPQA5LfahgRZvsTqEb1pEb1v9QoYrvX0q8nKx5qosYvCkohI_ZydRntj36q6A76pR9TpkmFKPYvY9CTE49fKiP2OCjU6m2zIs9FJkXE1IaqbXzO5pWu_eJ5wBG656jmT__H9z9jdwQt7EhxK3bZ1rhYwnO2bS9QfRYvvHFdAS97Lsg priority: 102 providerName: Directory of Open Access Journals |
| Title | Outnumbered: Control Prothrombin Time in Maddrey’s Discriminant Function Impacts Steroid Use but Not Mortality in Alcoholic Hepatitis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36552342 https://www.proquest.com/docview/2756664956 https://www.proquest.com/docview/2758109226 https://www.proquest.com/docview/2887607114 https://pubmed.ncbi.nlm.nih.gov/PMC9775026 https://doaj.org/article/95f2561b72f740eca20dae0bd4375099 |
| Volume | 11 |
| WOSCitedRecordID | wos000900517600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2079-7737 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702636 issn: 2079-7737 databaseCode: DOA dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2079-7737 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702636 issn: 2079-7737 databaseCode: M~E dateStart: 20120101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 2079-7737 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702636 issn: 2079-7737 databaseCode: M7P dateStart: 20120301 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2079-7737 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702636 issn: 2079-7737 databaseCode: BENPR dateStart: 20120301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2079-7737 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702636 issn: 2079-7737 databaseCode: PIMPY dateStart: 20120301 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB7RFiQuvAuGEi0SBy6m9nr94oLakqg9JFhApXCyvA-DJbBL7CBxQdz4Dfw9fgkzayeQCnpBihIlu4k2mtc3u7PfADwuQt8IyZWLiVfqilBFrvSKxI0NwmVdpjpSwjabiGezZD5Ps2HDrR3KKlc-0Tpq3SjaI98nmvIoIjj__OyTS12j6HR1aKGxBTvEkhDY0r1svceC6swjOp0kRp8As_v9gdkIDZygQbARjCxn_9-A5vl6yT8C0OT6_y79BlwboCc76HXlJlwy9S240jej_HIbvr9cdn1_EKOfsaO-hJ1li4Y6KXzEBJrRdRGGr1P0VqgBP7_9aNmLivxOX0_DJhgkSdDsxN69bNlrlFpTaXbaGiaXHZs1HZtawI_gn37qoO_QWyl2bKi2u6vaO3A6Gb85OnaHNg2uCrnXuUKmgeIqRN-qvdIgwDNSSu1pE6Wm4LpAQWjha7R9HcRJie-UKcnwY1H6hQl2YbtuanMPmOKixKAdSyFSIU2QmkhTV1KEISrx4sKBpyt55WrgMKdWGh9yzGVIwPk5ATvwZP2Fs56-499TD0kB1tOId9t-0Cze5YMZ52lYIkb0ZczLWHhGFdzThfGkFgFBr9SBvZUK5IMzaPPf8nfg0XoYzZjOZoraNEs7J_G9FMHwBXMwIBAdoC8cuNtr5Hq1QRSGPBDcgXhDVzf-zuZIXb23dOKYAYRoJ_cvXvoDuMrp5oePj2gPtrvF0jyEy-ozKsZiBFvxPBnBzuF4lr0a2Y2NkbVFev46xpHsZJq9_QW3PUO1 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtNAFL0qBQQb3g9DgUECiY2pPR4_Bgmh0hKlahMi0UrdGc_DYAnsEjug7tjxDfwEH8WXcK_tBFJBd10gRYpiTyzHOffMufadewAeZaFvheLaxcRLuiLUkau8LHFji3LZ5NJEWrRmE_F4nBwcyMkK_JivhaGyyjkntkRtKk33yNepTXkUkZx_cfjJJdcoero6t9DoYLFjj75gylY_397C__cx54NXe5tDt3cVcHXIvcYVSgaa6xCpwHi5RT1ilVLGMzaSNuMmQ5IwwjcIVRPESY6ftM0Jp7HI_cwGeNwzcBZlBE_aUsHJ4p4Ohg-P6GkodRAKAumt952UkFBIigRLk1_rEfA3YXu8PvOPCW9w-X-7VFfgUi-t2UYXC1dhxZbX4Hxntnl0Hb69njWd_4k1z9hmV6LPJtOKnCI-qqJktByG4fsI2RgR_vPr95ptFcSrXb0QG6AIICCz7XZtac3eICqrwrD92jI1a9i4atioTWgwuaFDbXQOxIVmQ0u1601R34D9U7kKN2G1rEp7G5jmIkdREishpFA2kDYy5LqKMksnXpw58HSOj1T3PdrJKuRDirkaASo9BigHniy-cNi1J_n30JcEuMUw6ivebqim79KeplIZ5qiBfRXzPBae1Rn3TGY9ZURA0lI6sDaHXNqTXZ3-xpsDDxe7kabo2VNW2mrWjkl8T6LYP2EMTnjU7tAXDtzqImBxtkEUhjwQ3IF4KTaWfs7ynrJ437ZLxwwnxLi8c_KpP4ALw73Rbrq7Pd65Cxc5rXLx8RWtwWozndl7cE5_RpBM77cxz-DtaUfOL9Gzm8Y |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtNAFL0qBSo2vB-GAoMEEhsTezy2M0gIlYaoUUmIBJW6M56HiyWwS-yAumPHN_ArfA5fwr22E0gF3XWBFCmKPbEc59wz59p37gF4mIa-FYprFxMv6YpQR67y0r4bW5TLJpMm0qIxm4gnk_7-vpyuwY_FWhgqq1xwYkPUptR0j7xHbcqjiOR8L-vKIqaD4fPDTy45SNGT1oWdRguRXXv0BdO36tlogP_1I86HL99u77idw4CrQ-7VrlAy0FyHSAvGyyxqE6uUMp6xkbQpNykShhG-QdiaIO5n-EnbjDAbi8xPbYDHPQNnYxE1pDCOp8v7OxhKPKIno9RNKAik1-u6KiG5kCwJVibCxi_gbyL3eK3mH5Pf8NL_fNkuw8VOcrOtNkauwJotrsL51oTz6Bp8ez2vW18Ua56y7bZ0n01nJTlIfFR5wWiZDMP3MbI0Iv_n1-8VG-TEt20dERuiOCCAs1Gz5rRibxCtZW7YXmWZmtdsUtZs3CQ6mPTQobZaZ-Jcsx1LNe11Xl2HvVO5CjdgvSgLewuY5iJDsRIrIaRQNpA2MuTGivJL9704deDJAiuJ7nq3k4XIhwRzOAJXcgxcDjxefuGwbVvy76EvCHzLYdRvvNlQzg6Sjr4SGWaojX0V8ywWntUp90xqPWVEQJJTOrC5gF_SkWCV_MaeAw-Wu5G-6JlUWthy3ozp-57EJOCEMTgRUhtEXzhws42G5dkGURjyQHAH4pU4Wfk5q3uK_H3TRh0znxBj9PbJp34fNjBgklejye4duMBp8YuPr2gT1uvZ3N6Fc_ozYmR2rwl_Bu9OO3B-AYEHpIQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Outnumbered%3A+Control+Prothrombin+Time+in+Maddrey%27s+Discriminant+Function+Impacts+Steroid+Use+but+Not+Mortality+in+Alcoholic+Hepatitis&rft.jtitle=Biology+%28Basel%2C+Switzerland%29&rft.au=Healey%2C+Marcus&rft.au=Sterling%2C+Richard+K&rft.date=2022-12-16&rft.issn=2079-7737&rft.eissn=2079-7737&rft.volume=11&rft.issue=12&rft_id=info:doi/10.3390%2Fbiology11121833&rft_id=info%3Apmid%2F36552342&rft.externalDocID=36552342 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2079-7737&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2079-7737&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2079-7737&client=summon |